Posts by Mourabit Halima

Differential diagnosis of chronic lymphoproliferative disorders (CLPD) remains a major challenge in hematology. Given the blurred boundary between reactive lymphoid proliferation and clonal proliferation, as well as the substantial overlap in morphological and immunophenotypic features among different subtypes, avoiding misdiagnosis and missed diagnosis is of critical importance. During the 2026 Cross-Strait Hematology Academic Conference, Oncology Frontier – Hematology Frontier invited Professor Wei Xu of the First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital) to systematically explain the diagnostic approach integrating basic morphology, flow cytometric immunophenotyping, and molecular genetic testing. Professor Xu also provided an in-depth analysis of strategies for resolving challenging CLPD cases, offering authoritative guidance for clinicians to establish a standardized, multidimensional, and precise classification system for these disorders.

Editor's Note: In the golden autumn season, colleagues from across the mountains and seas gathered together. The 2026 Cross-Strait Hematology Academic Conference was held in Zhuhai, Guangdong, from August 21…

Medical progress is driven not only by clinical practice and scientific innovation, but also by cross-regional exchange, mutual learning, and the transmission of knowledge and experience. Looking back at the history of hematology collaboration among the Chinese mainland, Taiwan, Hong Kong, and Macao—from the “seeds of life” transported across the Taiwan Strait to continuous breakthroughs in transplantation technology, and from exchanges among young physicians to deepening medical collaboration—each interaction has contributed to advances in diagnosis and treatment and enabled more patients to benefit from improved care.

On August 21, 2026, the 14th Lu Daopei Hematology Forum officially opened at Hebei Yanda Lu Daopei Hospital. Over the past 14 years, the conference has built a strong academic foundation. This year's meeting focused on cutting-edge topics including hematopoietic stem cell transplantation, cellular immunotherapy, and precision diagnosis and treatment of hematologic diseases, bringing together experts and scholars from across China to discuss advances in the field. During the conference, Oncology Frontier – Hematology Frontier invited Professor Xian Zhang of Hebei Yanda Lu Daopei Hospital for an interview. He shared his insights into the evolving treatment landscape of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), the timing and clinical value of immunotherapy, and strategies for managing treatment-resistant and relapsed disease.